Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
AR and prostate cancer are reported together in 13 articles.
Gene
AR
- HGNC
- HGNC:644
61articles
61mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Prostate cancer
218articles
218mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
13 records shown · first 60Unveiling Ligand-Induced Conformational Changes in Mutant AR-LBD: Molecular Dynamics Insights into the Androgen Receptor-Coactivator Mechanism.
PMID 40841914 | DOI 10.1021/acs.jcim.5c01406 · Journal of chemical information and modeling · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “The androgen receptor (AR) is a nuclear receptor involved in regulating gene expression, maintaining the sexual phenotype, and contributing to the development of prostate cancer (PCa).” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “The androgen receptor (AR) is a nuclear receptor involved in regulating gene expression, maintaining the sexual phenotype, and contributing to the development of prostate cancer (PCa).” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | F876L | “In addition, F876L and T877A mutations in AR-LBD alter the ligand-to-coactivator allosteric pathway involving the coactivator, helix 3 (H3), helix 4 (H4), the loop between H3-H4, and helix 12 (H12), potentially converting the AR-apalutamide complex from an antagonistic to an agonistic state.” | 0.82 | literature_variant_regex_v2 |
| variant | T877A | “In addition, F876L and T877A mutations in AR-LBD alter the ligand-to-coactivator allosteric pathway involving the coactivator, helix 3 (H3), helix 4 (H4), the loop between H3-H4, and helix 12 (H12), potentially converting the AR-apalutamide complex from an antagonistic to an agonistic state.” | 0.82 | literature_variant_regex_v2 |
Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligand binding domain.
PMID 40992974 | DOI 10.1016/j.urolonc.2025.08.009 · Urologic oncology · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “BACKGROUND: The mutations in the Androgen Receptor (AR) known as H874Y in prostate cancer greatly influence cellular signaling and execute the cell proliferation.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Deciphering the role of zingiber officinale phytochemicals for the treatment of prostate cancer: Interactions of phytochemicals with androgen receptor prostate cancer mutant H874Y ligand binding domain.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | H874Y | “BACKGROUND: The mutations in the Androgen Receptor (AR) known as H874Y in prostate cancer greatly influence cellular signaling and execute the cell proliferation.” | 0.82 | literature_variant_regex_v2 |
PROTACs in the Management of Prostate Cancer.
PMID 37175108 | PMCID PMC10179857 | DOI 10.3390/molecules28093698 · Molecules (Basel, Switzerland) · 2023 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “PROTACs in the Management of Prostate Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | FOXA1 | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
| gene | PTEN | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
Calcium Activation of the Androgen Receptor in Prostate Cells.
PMID 38131032 | PMCID PMC10733593 | DOI 10.1155/2023/9907948 · International journal of endocrinology · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “Castration resistance is due, in part, to intratumoral and/or adrenal synthesis of androgens, overexpression or mutation of the androgen receptor (AR), stabilization of AR by chaperones, and ligand-independent activation of AR.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “BACKGROUND: Although prostate cancer patients initially respond to androgen deprivation therapy, most patients progress to a resistant phenotype.” | 0.98 | phenotype_alias_lexicon_v2 |
Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.
PMID 35456461 | PMCID PMC9030534 | DOI 10.3390/genes13040655 · Genes · 2022 · 10 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |
| gene | MYC | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |
Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.
PMID 36733939 | PMCID PMC9887525 | DOI 10.3389/fgene.2022.1096071 · Frontiers in genetics · 2022 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “Functional depletion of METTL3 resulted in upregulation of the androgen receptor (AR), together with 134 AR-regulated genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | METTL3 | “For this reason, this study used immunohistochemistry and functional studies to investigate the mechanistic and clinical significance of the METTL3, METTL14, WTAP and CBLL1 components of the m6A methyltransferase complex in PCa specimens and cell lines.” | 0.98 | hgnc_dict_v1 |
| gene | METTL14 | “For this reason, this study used immunohistochemistry and functional studies to investigate the mechanistic and clinical significance of the METTL3, METTL14, WTAP and CBLL1 components of the m6A methyltransferase complex in PCa specimens and cell lines.” | 0.98 | hgnc_dict_v1 |
A patient-driven clinicogenomic partnership for metastatic prostate cancer.
PMID 36177448 | PMCID PMC9518748 | DOI 10.1016/j.xgen.2022.100169 · Cell genomics · 2022 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “Among molecular data from 333 patient partners (572 samples), exome sequencing of 63 tumor and 19 cell-free DNA (cfDNA) samples recapitulated known findings in MPC, while inexpensive ultra-low-coverage sequencing of 318 cfDNA samples revealed clinically relevant AR amplifications.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “A patient-driven clinicogenomic partnership for metastatic prostate cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents.
PMID 33869816 | PMCID PMC8035491 | DOI 10.1016/j.heliyon.2021.e06227 · Heliyon · 2021 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “However, AR mutation (F876L) converts Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “The androgen receptor inhibitor, Enzalutamide, proved effective against castration resistance prostate cancer, has demonstrated clinical benefits and increased survival rate in men.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | F876L | “However, AR mutation (F876L) converts Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance.” | 0.82 | literature_variant_regex_v2 |
Identification of Potential Genes for Benign Prostatic Hyperplasia and Prostate Cancer Susceptibility in Four X-chromosome Regions with High Frequency of Microvariant Alleles.
PMID 32856855 | PMCID PMC7771924 | DOI 10.31557/APJCP.2020.21.8.2271 · Asian Pacific journal of cancer prevention : APJCP · 2020 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “As TBL1, AR, LDOC1, and RPL10 genes are located at regions Xp22.31, Xq11.2-12, Xq26.2, and Xq28, respectively, these genes could play an essential role in PrCa or BPH.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Identification of Potential Genes for Benign Prostatic Hyperplasia and Prostate Cancer Susceptibility in Four X-chromosome Regions with High Frequency of Microvariant Alleles.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | LDOC1 | “As TBL1, AR, LDOC1, and RPL10 genes are located at regions Xp22.31, Xq11.2-12, Xq26.2, and Xq28, respectively, these genes could play an essential role in PrCa or BPH.” | 0.98 | hgnc_dict_v1 |
| gene | RPL10 | “As TBL1, AR, LDOC1, and RPL10 genes are located at regions Xp22.31, Xq11.2-12, Xq26.2, and Xq28, respectively, these genes could play an essential role in PrCa or BPH.” | 0.98 | hgnc_dict_v1 |
Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other.
PMID 30644608 | DOI 10.1002/mc.22975 · Molecular carcinogenesis · 2019 · 15 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “Network analysis showed that these genes are upstream of important functions including prostate gland development, tumor recurrence, prostate cancer-specific survival, tumor progression, cancer mortality, long-term survival, cancer recurrence, angiogenesis, and AR.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | AKR1C3 | “AKR1C3, BRCA1, BRCA2, CHGA, CYP19A1, HOXB13, KLK3, and PTEN contained the highest number of 3'UTR, 5'UTR, CDs, Intergenic, and Intronic variants.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA1 | “AKR1C3, BRCA1, BRCA2, CHGA, CYP19A1, HOXB13, KLK3, and PTEN contained the highest number of 3'UTR, 5'UTR, CDs, Intergenic, and Intronic variants.” | 0.98 | hgnc_dict_v1 |
Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules.
PMID 28655783 | PMCID PMC5628124 | DOI 10.1158/1535-7163.MCT-17-0176 · Molecular cancer therapeutics · 2017 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “The androgen receptor (AR) is a ligand-dependent transcription factor that controls the expression of androgen-responsive genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “A key step in androgen action, which is amplified in castration-resistant prostate cancer (CRPC), is AR nuclear translocation.” | 0.98 | phenotype_alias_lexicon_v2 |
Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor.
PMID 26176602 | PMCID PMC4503479 | DOI 10.1371/journal.pone.0128495 · PloS one · 2015 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “The androgen receptor (AR) is a member of the steroid receptor superfamily that regulates gene expression in a ligand-dependent manner.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “The NTD of the AR plays a key role in AR transactivation including androgen-independent activation of the AR in castration-resistant prostate cancer (CRPC) cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | PABPC1 | “Mass spectrometry analysis of the pulled down proteins identified poly (A) binding protein cytoplasmic 1 (PABPC1) interaction with this region of the AR.” | 0.98 | hgnc_dict_v1 |
Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia.
PMID 15310009 | PMCID PMC6147814 | DOI 10.5144/0256-4947.2004.21 · Annals of Saudi medicine · 2004 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | AR | “We analysed the polymorphic CAG and GGN repeats sequence in exon 1 of the AR gene to determine if the number of repeats might be an indicator of PRCa risk in patients with BPH.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | GGN | “Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia.” | 0.98 | hgnc_dict_v1 |